Skip to main content
. 2019 Mar 16;11(3):375. doi: 10.3390/cancers11030375

Figure 3.

Figure 3

Immunoblot expression of pHER2 in pertuzumab treated CHO-K6 cells. CHO-K6 cells were treated with 0.1, 1 and 10 μg/mL pertuzumab, 10 μg/mL trastuzumab and their combination for 60 min. Ten μg/mL human IgG and 20 μM CP-724714 were used as mock and positive controls respectively. The expression of (A) total HER2, (B) pY1005, (C) pY1127, (D) pY1139, (E) pY1196, (F) pY1221/1222 and (G) pY1248 HER2 was monitored by immunoblotting. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.